文献速递浆细胞疾病淋巴瘤

CD8 效应 T 细胞增强 Teclistamab 在 BCMA 暴露与未暴露的多发性骨髓瘤中的缓解

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
PubMed 文献 · Blood Adv · 2024-01-01

这项真实世界回顾性研究纳入 52 例晚期复发/难治多发性骨髓瘤患者,评估商业化 teclistamab 的疗效与免疫相关因素。总体缓解率为 64%,既往接受过抗 BCMA 治疗者缓解率为 50%。治疗前浆细胞 BCMA 表达水平与缓解无关,而效应 CD8+ T 细胞群与缓解相关、调节性 T 细胞群与未缓解相关。

要点

  • teclistamab 治疗 52 例晚期 R/RMM 总体缓解率为 64%。
  • 既往接受抗 BCMA 治疗者缓解率为 50%。
  • 治疗前浆细胞 BCMA 表达水平与缓解无关。

核心结论

  • 在晚期复发/难治多发性骨髓瘤真实世界中,teclistamab 高效,既往抗 BCMA 暴露者仍可缓解。
  • 治疗前免疫状态可能参与结局,并可能作为指导患者管理的生物标志物特征。

研究设计与样本

  • 真实世界回顾性研究,纳入 52 例接受商业化 teclistamab 的晚期复发/难治多发性骨髓瘤患者,同时采集临床结局与治疗反应的免疫相关指标。

主要发现

  • 总体缓解率为 64%。
  • 既往接受过抗 BCMA 治疗的患者缓解率为 50%。
  • 治疗前浆细胞 BCMA 表达水平与缓解无关。
  • 治疗前全面免疫分析显示效应 CD8+ T 细胞群与治疗缓解相关,调节性 T 细胞群与未缓解相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Firestone RS, McAvoy D, Shekarkhand T, et al. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma. Blood Adv. 2024. PMID: 37878808. doi:10.1182/bloodadvances.2023011225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。